Project Grant R56NS143102
- The National Institute of Neurological Disorders and Stroke awarded The Trustees of Columbia University in the City of New York $126,900 on March 7, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to exploit RNA biogenesis, specifically alternative splicing programs, to accelerate maturation of human neurons in vitro and to develop models of age-related tauopathies. The research addresses a fundamental...
- The National Institute on Aging awarded New York University $422,297 under the Aging Research program (CFDA 93.866) on February 15, 2026, to investigate mechanisms of dysregulated protein synthesis in human neurons carrying frontotemporal dementia–associated tau mutations. The project uses human induced pluripotent stem cell–derived neurons bearing FTD-associated tau mutations to model how pathogenic tau disrupts protein synthesis. In the first aim, researchers will determine the impact of...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded Yale University $667,613 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research examining ferroptosis—iron-induced programmed cell death—in erythrocytes within intracerebral hemorrhage hematomas. The project investigates how heme induces...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services National Institutes of Health, awarded The Research Foundation for the State University of New York $645,070 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating mitochondrial gene regulation in central nervous system development, with focus on how the transcription...
- The National Institute on Aging awarded the University of South Carolina $249,000 on August 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the effects of frontotemporal dementia and amyotrophic lateral sclerosis mutations in RNA-binding proteins on mRNA transport and local translation. The research uses induced pluripotent stem cell-derived neurons with CRISPR-edited FTD/ALS mutations in RNA-binding proteins (TDP-43, FUS, HNRNPA1, HNRNPA2, MATR3, and TIA1) to determine...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services National Institutes of Health, awarded $671,988 to the Winifred Masterson Burke Medical Research Institute, Inc. on September 11, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The recipient will conduct research on cross-talk between sarmoptosis and ferroptosis in hemorrhagic stroke, specifically...
- The National Institute of Neurological Disorders and Stroke awarded The Leland Stanford Junior University $124,794 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate microglial iron and lipid dysregulation in TDP-43-related neurodegeneration. The funded research will determine whether TDP-43-related neurodegeneration drives microglial ferroptosis by affecting microglial iron and lipid metabolism,...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $1.54M to Regenerative Research Foundation under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on June 1, 2025, for a 24-month project period concluding May 31, 2027. The award funds the development and validation of a novel induced pluripotent stem cell (iPSC)-based model to study frontotemporal dementia (FTD) caused by MAPT...
- The National Institute of Neurological Disorders and Stroke awarded the University of Southern California $1.245 million on August 18, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate mechanisms of differential vulnerability in the central nervous system and their implications for translating preclinical findings to successful clinical trials. The research examines why neurons, glia (astrocytes and microglia),...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
The National Institute of Neurological Disorders and Stroke awarded The Trustees of Columbia University in the City of New York $565,022 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of reactive oxygen species and ferroptosis in frontotemporal dementia. The research will assess mechanisms of neurodegeneration in frontotemporal dementia using in vitro and in vivo models. Work includes assays on human FTD patient induced pluripotent stem cell–derived neurons to evaluate the effects of reactive oxygen species on ferroptosis, tau pathology, and neurite health; testing the effects of the proinflammatory protein osteopontin on reactive oxygen species production, mitochondrial function, and cell death in FTD patient neurons; and transplanting FTD patient neural cells into mouse brain tissue followed by treatment with ferroptosis inhibitors and analysis via histology, single-nucleus RNA sequencing, and protein analysis of microdissected neuronal grafts. Performance occurs in New York, New York. The period of performance runs from September 1, 2026, through August 30, 2027. The assistance type is a Project Grant. This award supports extramural research seeking to advance understanding of neurological disease mechanisms and identify potential molecular targets and therapeutic compounds.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $565.0k | 8/28/26 |